About Fibronectin type III domain-containing protein 10
Fibronectin type III domain-containing protein 10 (FNDC10) is a protein
from Homo sapiens identified by UniProt accession
F2Z333, 226 residues long.
MolForge cross-references it against 0 known binders and
13 disease associations.
Target properties
| Protein name | Fibronectin type III domain-containing protein 10 |
|---|
| UniProt accession | F2Z333 |
|---|
| Gene | FNDC10 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 226 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (13)
Diseases linked to this target (Open Targets).
- body fat percentage · score 0.06
- sex hormone-binding globulin measurement · score 0.06
- serum alanine aminotransferase measurement · score 0.05
- low density lipoprotein triglyceride measurement · score 0.05
- high density lipoprotein cholesterol measurement · score 0.05
- aspartate aminotransferase measurement · score 0.05
- IGF-1 measurement · score 0.04
- visceral adipose tissue measurement · score 0.02
- serum albumin measurement · score 0.02
- Tetralogy of Fallot · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-F2Z333-F1 | alphafold | PREDICTED | 76.47 | — |
Amino-acid sequence (226 residues)
MRAPPLLLLL AACAPPPCAA AAPTPPGWEP TPDAPWCPYK VLPEGPEAGG GRLCFRSPAR GFRCQAPGCV LHAPAGRSLR ASVLRNRSVL LQWRLAPAAA RRVRAFALNC SWRGAYTRFP CERVLLGASC RDYLLPDVHD SVLYRLCLQP LPLRAGPAAA APETPEPAEC VEFTAEPAGM QDIVVAMTAV GGSICVMLVV ICLLVAYITE NLMRPALARP GLRRHP
Explore Fibronectin type III domain-containing protein 10 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets